While patients with KRAS G12C–positive cancer may benefit from treatment with CIT alone or in combination with chemotherapy [12, 13], numbers of patients with KRAS G12C-positive cancer were low in these previous studies, and it remains unclear how the benefit compares with that seen in patients with KRAS wild-type (WT) cancer. This evidence concerns the gene KRAS and cancer.